Skip to main content
. 2018 Dec 26;2(24):3648–3652. doi: 10.1182/bloodadvances.2018018614

Table 1.

Efficacy end points for the DASISION and ENESTnd trials

DASISION13 ENESTnd14
Imatinib Dasatinib Imatinib Nilotinib
400 mg daily (n = 260) 100 mg daily (n = 259) 400 mg daily (n = 283) 300 mg twice daily (n = 282) 400 mg twice daily (n = 281)
Cumulative MMR at 5 y, % 64 76 60 77 77
MR4.5 at 5 y, % 33 42 31 54 52
Progression to AP/BC, % 7 5 7 4 3
5-y OS (ITT), % 90 91 92 94 96
5-y PFS, % 86 85 91 92 96

AP, accelerated phase; BC, blast crisis; ITT, intention to treat.